BRCA1 and cancer: While hCCAR2 deletion could compromise cancer cells’ invasive properties or resilience to various stresses, thus inducing cancer cell death, hCCAR2 deletion in an HR-deficient background (e.g., BRCA1/2 mutant) may confer a growth advantage on cancer cells by restoring genetic stability.